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Abstract   
Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring 
several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection.  Deep immune profiling showed acute MIS-C patients had highly activated 
neutrophils, classical monocytes and memory CD8+ T-cells; increased frequencies of B-cell 
plasmablasts and double-negative B-cells. Post treatment samples from the same patients, 
taken during symptom resolution, identified recovery-associated immune features including 
increased monocyte CD163 levels, emergence of a new population of immature neutrophils 
and, in some patients, transiently increased plasma arginase.  Plasma profiling identified 
multiple features shared by MIS-C, Kawasaki Disease and COVID-19 and that therapeutic 
inhibition of IL6 may be preferable to IL1 or TNF- . We identified several potential 
mechanisms of action for IVIG, the most commonly used drug to treat MIS-C. Finally, we 
showed systemic complement activation with high plasma C5b-9 levels is common in MIS-C 














Infection of children with SARS-CoV-2, the viral cause of coronavirus disease 2019 (COVID-
19) is associated with two distinct outcomes.  The first is an acute infection of the respiratory 
tract that in most cases is asymptomatic or associated with mild respiratory symptoms 
(Castagnoli et al., 2020; Hoang et al., 2020) . The second is a rare, severe hyperinflammatory 
syndrome called Multisystem Inflammatory Syndrome in Children (MIS-C) by the World Health 
Organisation or paediatric inflammatory multisystem inflammatory syndrome temporally 
associated with SARS-CoV-2 infection (PIMS-TS) in the UK (Ahmed et al., 2020; 
Kanthimathinathan and Scholefield, 2020; Whittaker et al., 2020; Hoste et al. 2021). Several 
weeks after the primary infection children with MIS-C present with fever, inflammation and 
evidence of single or multi-organ failure that manifests with cardiac dysfunction, hypotension 
and life-threatening shock. This is accompanied by lymphopaenia and neutrophilia, both of 
which are rare in acute paediatric COVID-19 (Ahmed et al., 2020; Castagnoli et al., 2020; 
Hoang et al., 2020; Kanthimathinathan and Scholefield, 2020; Hoste et al., 2021).  
 
MIS-C does, however, share clinical features with several paediatric inflammatory conditions 
including toxic shock syndrome (TSS), macrophage activation syndrome (MAS) and Kawasaki 
Disease (KD).  KD is a systemic vasculitis that presents with symptoms of fever, rash, 
conjunctivitis, lymphadenopathy and cardiac complications that is believed to be triggered by 
an as yet unidentified infectious agent (McCrindle et al., 2017; Rivas and Arditi, 2020). Acutely 
ill KD patients have increased blood levels of both pro-inflammatory anti anti-inflammatory 
cytokines with lymphopaenia and neutrophilia (McCrindle et al., 2017). Untreated KD can 
cause coronary aneurysms but the risk is substantially reduced by treatment with intravenous 
immunoglobulin (IVIG) (McCrindle et al., 2017). This agent is used to treat a diverse range of 
autoimmune and inflammatory conditions but its mechanism of action remains poorly defined 
(Nimmerjahn and Ravetch, 2008; Nagelkerke and Kuijpers, 2014). While MIS-C shares 
features with KD there are also notable differences (Consiglio et al., 2020; Lee et al., 2020). 
For example, MIS-C patients often present with shock, cardiac dysfunction and 
hyperferritaemia, all of which are rarely seen in KD (McCrindle et al., 2017; Ahmed et al., 
2020; Hoste et al., 2021) .These differences suggest the underpinning pathology may differ 
between the two diseases potentially warranting different treatments. 
 
The optimal treatment strategy for MIS-C is unknown and there are no widely accepted 
guidelines on patient management. IVIG is the most commonly used anti-inflammatory agent 
followed by systemic corticosteroids(Ahmed et al., 2020; Hoste et al., 2021) and targeted 









(TNF-) pathways in a smaller number of cases (Hoste et al., 2021; Ahmed et al., 2020; Lee 
et al., 2020; Consiglio et al., 2020; Carter et al., 2020; Rodríguez-Rubio et al., 2021; Diorio et 
al., 2020; Henderson and Yeung, 2021; Gruber et al., 2020). Identifying the abnormal 
immunological features present in acutely ill untreated MIS-C patients is therefore important 
not only to understand the pathogenesis of this new disease but also to inform rational 
treatment selection. We therefore performed high dimensional analysis of blood and plasma 
samples from children with MIS-C, comparing them to healthy children and SARS-CoV-2 
negative KD patients recruited over the same time period. Analysis of longitudinal samples 
from patients identified multiple immunological changes occurring after treatment.  Our results 
provide a detailed insight into the immunopathology of MIS-C from acute disease into 
recovery. They suggest that, amongst cytokine inhibitors, agents targeting IL6 may be 
preferrable to those that that target IL1 or TNF-Furthermore, our data provide a rational 













Patient recruitment, treatment and clinical features 
Between late April and October 2020 at Birmingham Women and Children’s Hospital, a 
tertiary level paediatric hospital, we recruited 16 children meeting the MIS-C diagnostic criteria 
established by the UK Royal College of Paediatrics and Child Health (Table S1).  A surge of 
cases (50%) occurred approximately four weeks after SARS-CoV-2 cases were detected in 
the local community; subsequent cases accrued steadily over time (Figure 1A).  All 16 MIS-C 
cases were over 5 years of age and tested positive for anti-SARS-CoV2 antibodies (Figure 
1B and Table S1) (Perez-Toledo et al., 2020). Contemporaneously we recruited two patients 
with KD both of whom were under 5 years old and negative for anti-SARS-CoV-2 antibodies.  
Clinical laboratory tests showed all patients had elevated inflammatory markers, including 
ferritin (Figure 1C). Almost all MIS-C patients had high troponin and N-terminal pro B-type 
natriuretic peptide (NTpro-BNP, Figure 1C and data not shown).  Interestingly, all MIS-C 
patients were deficient in vitamin D. Patients’ length of hospital stay ranged between 5 to 16 
days and 88% of MIS-C patients were admitted to the paediatric intensive care unit (PICU) 
from 2 to 8 days (Figure 1D). Of the 16 MIS-C patients, 13 received IVIG with three MIS-C 
patients (and one KD patient) receiving a second IVIG infusion due to ongoing inflammation. 
Eight MIS-C patients received IV methylprednisolone and one, patient 13, received anti-IL6 
therapy (Tocilizumab). All 18 patients survived without long term cardiac complications at the 
time of last follow up.  
 
Clinical laboratory data shows neutrophilia is associated with severe disease in MIS-C.   
In accordance with previous reports (McCrindle et al., 2017; Ahmed et al., 2020; Feldstein et 
al., 2020; Hoste et al., 2021), both KD patients and almost all MIS-C patients had abnormally 
low lymphocyte and abnormally high neutrophils counts (Figure 1E).  The absolute number of 
monocytes was normal for the KD patients but at the lower limit of normal for almost all MIS-C 
patients. Analysis of longitudinal data showed these perturbations resolved following 
treatment, although this was slower for granulocytes which were still elevated once 
lymphocytes and monocytes had returned to normal (Figure S1). Using principal component 
analysis to obtain a global view of the clinical laboratory data showed neutrophil count, CRP 
and ESR correlated with each other with monocyte and lymphocyte counts orthogonal to 
these features (Figure 1F).  All patients fell outside of the normal region to varying degrees.  
 
We next investigated the relationships between clinical features, absolute immune cell counts 
and demographics for the MIS-C patients (Figure 1G) (Vella et al., 2020). Clinical markers of 
cardiac and kidney dysfunction (troponin, pericardial effusion, urea and creatinine) positively 









observed multiple highly significant positive correlations between absolute neutrophil count 
and markers of inflammation (CRP), cardiac dysfunction (presence of pericardial effusion, 
levels of troponin, creatinine kinase and NTpro-BNP) and overall length of hospital stay.  
Additional clinical laboratory assays performed on a subset of patients showed that, in 
accordance with lymphopaenia, the absolute counts of CD4 and CD8 T-cells and B-cells were 
diminished. However, the relative proportion of these cells within the lymphocyte pool were 
generally unaltered (Figure 1H). Analysing the anti-SARS-CoV-2 antibody response in detail 
for eight MIS-C patients showed all eight had IgG and IgA antibodies but lacked IgM 
antibodies consistent with MIS-C developing weeks after virus infection occurred (Figure 1I) 
(Castagnoli et al., 2020; Hoang et al., 2020; Hoste et al., 2021). 
 
scRNA sequencing data show monocytes are profoundly altered in MIS-C and KD 
patients.  
To explore immune changes in MIS-C in more detail, we first performed an unbiased analysis 
by performing single cell RNA sequencing (scRNAseq) on the pre-treatment peripheral blood 
mononuclear cells (PMBCs) of two representative patients (P13 and P14) with MIS-C.  Both 
patients were admitted to PICU but patient P14 responded rapidly to one cycle of IVIG and 
stayed on PICU for three days whereas patient P13 stayed on PICU for eight days and 
received a second IVIG infusion, intravenous steroids and Tocilizumab, a monoclonal 
antibody against the interleukin-6 receptor, to control their disease.  A convalescent sample 
from P13 collected at discharge from PICU was also analysed. For comparative purposes we 
also analysed pre-treatment acute-stage PBMCs from patient KD2 who required two infusions 
of IVIG (Figure 1D). All four samples were thawed, processed and sequenced in the same 
experiment. Unsupervised clustering of 10,031 cells produced 19 different clusters comprising 
all major lymphocyte subsets (Figure 2A, S2, S3, S4). Analysing each patient separately, we 
observed that all possessed lymphocytes assigned to one of the nine B-cell, T-cell or NK cell 
clusters although the frequencies of cells within each of these clusters varied between 
patients and, for P13, from acute disease to convalescence (Figure 2B).  In contrast, each 
patient's monocytes were assigned to only one or two of the five different monocyte clusters. 
Four of these clusters corresponded to CD14+ classical monocytes and for each sample 
these cells were assigned to a separate cluster Based on CD14 and CD16 expression the fifth 
monocyte cluster (cluster nine) contained intermediate and non-classical monocytes, and 
these varied markedly in frequency between samples: abundant in the acute sample from 
patient KD2, less frequent in the acute sample from patient P13 and scarce in the 
convalescent sample from this same patient but also the acute sample from P14. The marked 








comparatively inert, suggested monocyte-specific changes were present rather than a batch 
effect.  
 
Pathway analysis (Figure S5) on genes upregulated in each of the major immune subsets, 
relative to the same subset in the convalescent sample from P13, showed highly significant 
enrichment of genes annotated with GO-term 0002446 ‘Neutrophil mediated immunity’ in 
CD14+ monocytes from patient KD2 (p=3x10-34) and P13 (p=7x10-31). Although labelled as 
neutrophil mediated immunity, this pathway contains many genes expressed by monocytes. 
Genes upregulated in CD14+ monocytes from KD2 and P13 included: genes involved in 
complement function and regulation (CD35 and CD55); adhesion, homing and scavenger 
receptors (CD36, CD62L, CD63); Fc receptors (FCGR2A and FCER1G); alarmin related 
S100A molecules (S100A8, S100A9, S100A11 and S100A12) and regulation of innate cell 
mediated inflammation (SERPINB1).  Due to the lack of intermediate/non-classical monocytes 
in the convalescent sample we did not perform GO-term analysis for this subset. 
 
Repeating dimensionality reduction and clustering analyses on just the subset of data from 
the four samples that represented monocytes yielded nine monocyte clusters (numbered mc0 
to mc8) that could now be assigned to the three canonical monocyte subsets (Wong et al., 
2011) (Figure 2C, S6).  Clusters mc0, mc1, mc3, mc4 and mc5 were CD14+ CD16- classical 
monocytes (CM), mc6 (CD14int CD16int ) comprised intermediate monocytes (IM) while mc2 
(CD14lo CD16hi) comprised non-classical monocytes (NCM). Previous studies have shown 
that the large majority of monocytes in the blood of healthy children are CM with only small 
populations of IM and NCM present (Wong et al., 2011).This distribution was distorted in the 
acute KD sample with high frequencies of IM (cluster mc6, 8%) and NCM (cluster mc2, 38%) 
(Figure 2D). The acute sample from MIS-C patient P13 also had an abnormally high 
frequency of NCM (34% of total monocytes) but lacked IM. Upon recovery, monocytes from 
MIS-C patient P13 returned to the normal state with only the CM population present in their 
convalescent sample.  Examining gene expression in more detail (Figure 2C, S7) we 
detected mRNA encoding IL-1 in the mc6 intermediate monocytes abundant in patient KD2 
but detected low or no transcripts encoding other monocyte-associated cytokines including 
IL6, IL8 (gene CXCL8), IL10, IL18, TNF- or IL1 receptor antagonist (IL1RA, gene IL1RN).  
 
Mass cytometry shows monocytes granulocytes and CD8 memory T-cells are 
contemporaneously activated in MIS-C and KD patients   
To examine the above changes in more patients and to extend our analysis to granulocytes, 









(Ahmed et al., 2020; Hoste et al., 2021), we used the scRNAseq analysis as a guide to 
develop a MIS-C focussed 38 marker mass cytometry panel (Table S2) and used this to 
investigate whole blood samples from 7 patients (6 MIS-C and 1 KD) and 7 healthy children. 
The former included patients P13, P14 and KD2 (whose PBMCs were examined by scRNA 
sequencing) and four additional MIS-C patients from our cohort. Samples were collected 
during the acute stage, two days after IVIG administration and upon discharge from PICU or 
hospital (Figure S8). Acute stage samples were taken before IVIG with one exception, the 
sample from P14, which was collected 8 hours after IVIG infusion.    
 
Unsupervised dimensionality reduction and clustering of 224,000 cells (16,000 from each of 
the seven healthy children, six MIS-C patients and one KD patient) identified 24 clusters 
comprising plasmacytoid dendritic cells (pDCs), T-cells, B-cells, NK-cells and monocytes 
(Figure 3A and Figure S9). Comparing the combined data from 7 healthy children to 6 
acutely ill patients we observed profound changes in monocyte cluster abundance as noted in 
the scRNAseq data analysis. We next evaluated the data for each individual (Figure 3B). The 
frequency of seven clusters was significantly different in MIS-C patients compared to healthy 
children. Note that we chose not to include the KD patient in this statistical analysis but show 
their results on the plot as an exemplar of this disease. Based on marker expression (Figure 
S9) the frequency of activated CM (cluster 20) was significantly increased in MIS-C with a 
concomitant decrease of non-activated CM (cluster 17). There was no significant difference in 
the frequency of both IM and NCM (cluster 12), but we noted patient MIS-C P13 and KD2 had 
high frequencies of these cells consistent with their scRNAseq data. Examining other immune 
cell types, MIS-C patients showed a small but significant increase in CD19+ CD38hi CD27hi B-
cell plasmablasts (cluster 5) and a much larger increase in IgD-CD27- double negative (DN) 
B-cells (cluster 2). These DN B-cells lacked CD11c consistent with them being the recently 
proposed DN1 B-cell subset (Sanz et al., 2019). T-cell cluster 8 and pDCs (cluster 11) were 
both decreased in MIS-C patients relative to controls.  
 
We next examined the immune features associated with disease recovery. IVIG acts rapidly, 
resolving inflammation in most KD patients two days after infusion although a minority require 
additional treatments due to ongoing inflammation or recrudescence (Newburger et al., 1991). 
We therefore re-sampled our patients two days after IVIG infusion and then upon discharge 
from ICU or hospital (Figure S8).  Compared to their pre-treatment samples, monocytes in the 
post-IVIG samples had started to normalise with decreases in the frequency of cells in 
activated CM and IM/NCM (cluster 20 and 12 respectively) and increases in the frequency of 
non-activated CM (cluster 17). This reversion to normality continued further to PICU 









those of healthy children (Figure 3C and 3D). Reversion proceeded rapidly for patient P13, 
who had the highest frequency of activated CM (cluster 20) at the acute stage. Examining the 
phenotype of each monocyte cluster over time, we observed that levels of CD163 increased 
on the non-activated CM cells (cluster 17) after IVIG (Figure 3E). Interestingly the level of 
CD64 also increased on these cells at this time (albeit to a lower degree than the highly 
activated cluster 20 CM cells) suggesting the CD163-positive CM had also undergone a 
degree of activation. The CD163 CD64 double positive cells were present in 3 of the 4 MIS-C 
patients who received IVIG and from whom we obtained post-IVIG samples (Figure S10). 
They were also present in the discharge sample from KD patient KD2 which was collected two 
days after a second cycle of IVIG was administered due to ongoing inflammation. Thus, their 
appearance was coincident with ongoing disease resolution (SI Figure 8).   
 
Examining the expression of different proteins across the fourteen T-cell clusters (Figure S9) 
we noted most T-cells in MIS-C patients were CD45RA+ CD27+ naïve cells. One cluster of 
CD8 non-naïve T-cells (cluster 13, with low CD45RA and CD27 expression) expressed HLA-
DR, a marker of T-cell activation(Maecker et al., 2012).To explore this in more detail we used 
CD27 and CD45RA to manually gate CD8+ and CD4+ T-cells into the four canonical T-cell 
subgroups: naïve (Tn), central memory (Tcm), effector memory (Tem) and terminally 
differentiated effector memory re-expressing CD45RA (TemRA) (Sallusto et al., 1999) (Figure 
S11).  As expected for children, and consistent with the unsupervised clustering, we found all 
healthy donors and patients had a high proportion of naïve T-cells (Figure 4A) with the 
highest in the KD patient likely due to their younger age (Taylor et al., 2019; Lakshmikanth et 
al., 2020). Comparing healthy children to MIS-C patients we found no significant differences in 
the distribution of the four subgroups in CD8 or CD4 T-cells (Figure S11C).  However, MIS-C 
patients had a significantly higher proportion of HLA-DR positive activated CD8-T-cells at the 
acute stage of disease (Figure 4B).  In MIS-C patients, only 2% of Tn cells were HLA-DR 
positive whereas 35% of Tcm and 30% of Tem CD8+ T-cells were HLA-DR positive. The 
proportion of HLA-DR positive CD8 T-cells remained high after IVIG and, for one patient (P7), 
increased markedly (Figure 4C). At discharge, the proportion of activated cells had declined 
but were still higher than controls. In contrast, only a small proportion of CD4 T-cells 
expressed HLA-DR and only Tcm were significantly higher than controls at the acute stage. 
The KD patient showed the same pattern of HLA-DR expression on their CD8+ and CD4+ T-
cell subsets.    
 
Turning to granulocytes, we manually gated and examined the CD66b+ CD16+ neutrophil 
population (Figure 5A). We compared equal numbers of cells (22,000) sampled from seven 









IVIG and 2 at time of discharge); for comparison we also examined cells from these same 
timepoints from patient KD2 (Figure 5B).  Both patient groups exhibited the same changes in 
phenotype, with decreased expression of the granulocyte maturity markers CD16 and CD10 
(Marini et al., 2017), and increased expression of the neutrophil activation marker CD64 
(Nagelkerke and Kuijpers, 2014), which was highest at the acute stage then slowly decreased 
after IVIG and at discharge, although levels were still raised at this time.   
 
Unsupervised dimensionality reduction and clustering of the total granulocyte population 
identified nine clusters (Figure 5C).  One cluster, cluster 1, present in patients and healthy 
children were eosinophils based on expression of FceR1, CD38, HLA-DR and lack of CD16 
and CD10 (Figure 5D). The other 8 clusters were neutrophils and these showed marked 
differences in abundance.  Healthy children had few cells classified into clusters 4,5,8 and 9 
whereas almost all cells in acutely ill MIS-C patients belonged to these clusters. This 
redistribution of neutrophils was driven by a dramatic decrease in CD10 and increase in CD64 
on patients’ neutrophils. Expression of both markers had begun to decrease towards healthy 
children’s levels after IVIG administration then further decreased at discharge, although the 
frequencies of all four activated clusters (clusters 4, 5, 8, 9) were still significantly higher at 
this time.  In contrast eosinophils (cluster 1) showed only modest changes in frequency and 
phenotype with only CD35 (complement receptor 1) expression varying over time.  
 
Granulocyte cluster 3 was present at very low frequency in healthy children (median 
frequency 0.16% of granulocytes), and in acutely ill MIS-C (0.11%) and KD (0.04%) patients.  
However, after IVIG the frequency of these cells increased 5 to 12-fold over pre-treatment 
values in the MIS-C patients (median frequency 0.81% range 0.30-2.7%) and 30-fold 
(frequency 1.6%) in the KD patient.  These cells continued to increase in frequency over time 
and at discharge their frequency was 70-fold to 204-fold higher than at the acute stage. At 
discharge they comprised 2.79% and 29.05% of total granulocytes in MIS-C patients P6 and 
P13 respectively.  This continued increase also occurred in the KD patient (KD2) with cluster 
3 cells having a frequency 280-fold higher in the discharge sample compared to the acute 
sample, comprising 14.0% of this patient’s granulocytes at discharge. Cluster 3 cells also 
possessed an unusual phenotype; they were clearly granulocytes based on their strong 
expression of the canonical granulocyte marker CD66b with their lack of CD16 and CD10 
indicating immaturity. However, they were different to all other granulocyte clusters as they 
lacked expression of CD11c, CD35 and CD55. Cluster 3 granulocytes in MIS-C patients and 
the KD patient but not healthy children, expressed CD64 indicating these cells were not only 










Pro- and anti- inflammatory cytokines are elevated in MIS-C and KD patients and 
arginase is increased after IVIG administration 
We next performed a wide-ranging analysis of 32 cytokines and chemokines in plasma 
samples from nine patients (eight MIS-C, one KD) and seven healthy children. These soluble 
immune mediators were selected based on the cellular changes we observed in MIS-C and 
KD, as well as prior studies on KD and, more recently, MIS-C patients(Lee et al., 2020; 
Consiglio et al., 2020; Carter et al., 2020; Rodríguez-Rubio et al., 2021; Diorio et al., 2020; Ko 
et al., 2015; Ching et al., 2020; Ren et al., 2015; Takeshita et al., 1999; Weng et al., 2013; 
Hokibara et al., 2016; Gruber et al., 2020). We selected assays capable of providing absolute 
quantification to allow data from our patients to be directly compared with historical data from 
KD and other inflammatory conditions. Comparing MIS-C patients to healthy children, we 
identified statistically significant differences for 16 of the 32 soluble mediators analysed 
(Figure 6A). MIS-C patients had significantly increased levels of the chemokines monocyte 
chemoattractant protein 1 (MCP-1/CCL2) and interferon gamma-induced protein 10 
(IP10/CXCL10), higher levels of the pro-inflammatory cytokines IL-6 and IL-18 but, at the 
same time, higher levels of anti-inflammatory cytokine IL-10. Soluble receptors of tumour 
necrosis factor alpha (sTNF-R1 and sTNFR2), CD40 ligand (sCD40L) and IL-2 (sCD25) were 
all higher in MIS-C patients as was interleukin-1 receptor antagonist (IL-1RA), a member of 
the IL1 family that binds the IL1-receptor to inhibit this pathway.  Plasminogen activator 
inhibitor 1 (PAI-1), pentraxin-3 (PTX3), myeloperoxidase (MPO) and IL-18 were also higher in 
MIS-C patients. For several pro-inflammatory cytokines and chemokines there was no 
difference between patients or the healthy donor controls, including: IL1-, IL-8 (CXCL8), IL-
17A, interferon-alpha2 (IFN-a2) interferon-gamma (IFN-) and TNF-.  We did not include the 
KD patient in the statistical analysis, but their acute blood sample had the same profile of 
cytokines, chemokines and other soluble factors as the acute MIS-C patients (Figure 6A). 
  
Principal component analysis divided patients into two broad groups (Figure 6B).  Acute MIS-
C samples were most distant from the healthy children and almost all patients migrated 
towards the healthy state after IVIG therapy, the exception being P13, a patient with 
particularly severe disease.  Examining each soluble mediator over the disease course 
(Figure 6C) we found that many decreased following treatments with IVIG or IVIG combined 
with steroids (Figure S8). These included both proinflammatory (IL-6, IP-10, MCP-1) and anti-
inflammatory (IL-10, IL-1Ra) molecules. A notable exception was arginase, levels of which in 
the acute phase of disease were not significantly higher than those in healthy children but 
increased dramatically for MIS-C patient P13 and patient KD2 in their post IVIG sample. 









alone. The increased quantity of arginase in these patients’ plasma was confirmed to be 
enzymatically active in an independent assay (Figure 6D). Finally, across all patients we 
noted a significant positive correlation between post-IVIG arginase levels and pre-treatment 
absolute number of neutrophils (r=0.91, R2=0.822, p=0.008), the main source of arginase in 
humans (Munder et al., 2005) but no correlation with lymphocytes or monocytes (Figure 6E).  
 
The complement system is a key part of the innate immune system and modulates adaptive 
immunity. Complement dysregulation has been repeatedly observed in COVID-19 (Holter et 
al., 2020; Magro et al., 2020; Zelek et al., 2020b). Quantification of nine complement markers 
(Figure 7A) revealed that complement protein C9 and C5b-9 (the terminal complement 
complex, TCC, indicative of ongoing terminal pathway activation) were significantly increased 
in MIS-C patients at the acute stage of disease. The terminal pathway of the complement 
system generates membrane attack complex (MAC) pores that lyse cells but which also have 
potent pro-inflammatory action (Morgan, 2016). Notably, levels of C5b-9 were highest in MIS-
C patient P13, who had the most severe disease, and lowest in KD patient KD2.  The 
complement regulator Factor I was also raised at the acute stage. After treatment, C5b-9 











MIS-C is a newly described and rare manifestation of SARS-CoV-2 infection of children that is 
clinically and temporally distinct to COVID-19 but shares features with several pediatric 
diseases including KD.  Current treatment for MIS-C relies on supportive care (e.g. vasoactive 
medication) in combination with immunomodulatory agents. The most frequently used agent is 
IVIG (Ahmed et al., 2020; Hoste et al., 2021) which has been used to successfully treat KD for 
decades (Nagelkerke and Kuijpers, 2014).  Although its mechanism of action is unknown IVIG 
acts rapidly, resolving inflammation in most KD patients within two days (Newburger et al., 
1991). To investigate the immunopathology of MIS-C, and how this alters in response to 
therapy, we performed high dimensional immune analysis on blood samples taken from MIS-
C and KD patients before treatment, 1-3 days after IVIG infusion when symptoms were 
resolving and upon ICU/hospital discharge.  
 
The clinical features of our MIS-C cohort were consistent with other studies. Patients were 
older than 5 years old, had high blood levels of inflammatory markers, ferritinaemia, 
neutrophilia, lymphopaenia and increased numbers of plasmablasts (Ahmed et al., 2020; 
Carter et al., 2020; Jiang et al., 2020; Vella et al., 2020; Hoste et al., 2021) .Neutrophilia has 
previously been reported to correlate with IVIG resistance in KD (Kanai et al., 2020) and 
disease severity in adult COVID-19 patients (Wang et al., 2020).  Our data revealed a 
significant positive correlation exists between increased neutrophil count and cardiac 
dysfunction, inflammation and disease severity in MIS-C. Since neutrophil count is a widely 
available test this observation provides a simple means for clinicians to assess disease 
severity and stratify patients in the future. Interestingly we also observed that all MIS-C 
patients on our study were deficient for vitamin D, which is linked to greater disease severity 
in KD (Stagi et al., 2016; Jun et al., 2017) and enhanced inflammation in general (Yin and 
Agrawal, 2014). In the UK vitamin D deficiency is common in the black and ethnic minority 
groups, which 15/16 of our MIS-C patients were from (Sutherland et al., 2020). We therefore 
suggest it is unlikely that vitamin D deficiency alone is responsible for the development of 
MIS-C but, given the wide-ranging effects of vitamin D on the immune system (Feketea et al., 
2021), this finding warrants further investigation in larger MIS-C cohorts.  
 
Our high dimensional analysis of acute MIS-C patients provides new insights into disease 
pathogenesis. Although in our study we were unable to directly compare MIS-C to COVID-19 
cases, we were able to identify several new immune features shared between the two 
diseases. First, we found that neutrophilia correlates with disease severity in MIS-C, as is the 
case for COVID-19 in adults but not children (Guan et al., 2020).  Neutrophils, which we and 









myeloperoxidase levels we detected in MIS-C patients’ plasma. Further characterisation of 
neutrophil effector molecules in MIS-C, particularly neutrophil elastase and neutrophil 
extracellular traps which have both been linked to KD and COVID-19 pathogenesis (Takeshita 
et al., 1999; Yoshida et al., 2020; Reusch et al., 2021)  are clearly important priorities for 
future investigation.  Second, we showed acute MIS-C patients had high plasma levels of 
pentraxin-3 (PTX3), an important innate immune mediator of resistance to viral infection and 
regulator of inflammation (Garlanda et al., 2018). PTX3 levels are raised in adult COVID-19 
patients with plasma levels serving as a strong prognostic indicator of mortality (Brunetta et 
al., 2020). Endothelial cells are a major source of PTX3 and increased levels are reported for 
various vasculopathies.  Third, we showed acute MIS-C patients had high levels of 
plasminogen activator inhibitor-1 (PAI-1), a marker of endothelial dysfunction that amplifies 
neutrophil-mediated inflammation via multiple mechanisms (Zmijewski et al., 2011; Ren et al., 
2015) and that is raised in multiple inflammatory conditions including trauma, sepsis and in 
adult COVID-19 patients (Zuo et al., 2021). Fourth, we showed the complement pathway was 
activated in MIS-C, as demonstrated by high levels of C9 and C5b-9. The latter is a marker of 
activation of the membrane attack complex, the final common pathway of complement 
activation. MAC pore formation lyses cells and acts as a potent inflammatory trigger activating 
cytokine production by monocytes and neutrophils (Morgan, 2016). Complement activation 
can also cause endothelial damage and could explain the shock common in MIS-C patients. 
Plasma levels of C5b-9 are raised in adult COVID-19 patients with high levels being 
associated with severe disease and respiratory failure (Holter et al., 2020; Zelek et al., 
2020b).  Notably, all four of the above immune features that have previously been described 
in COVID-19, and which we identify here in MIS-C, have also been observed in previous 
studies of children with KD (Ching et al., 2020; Polycarpou et al., 2021).  All four were also 
present in the KD patient we included in the high dimensional analyses, although we note 
their complement profile was distinct: high C9, low C5b-9 with high C1 inhibitor and factor H.  
 
Analysing MIS-C patients alongside a representative KD patient provided further insights into 
the two conditions. We acknowledge the limitation of analysing a single KD patient but 
highlight that their immune profile was consistent with evidence from multiple studies of larger 
numbers of KD patients. These include: lymphopaenia, neutrophilia; neutrophil activation; 
increased intermediate and non-classical monocytes; high CD64 expression on monocytes 
and neutrophils; raised levels of IL6, IL18, PAI-1, sCD25, sTNF-R, IP10, MPO and PTX3 
(Takeshita et al., 1999; Senzaki et al., 2003; Weng et al., 2013; Ko et al., 2015; Hokibara et 
al., 2016; Ching et al., 2020). Thus they serve as a valuable exemplar of the disease in our 
analyses.  MIS-C patients had all of the aforementioned features in common with KD with two 









subset unaltered in KD (Xu et al., 2019) . DN1 B-cells are increased during pathogenic and 
protective immune responses and may represent precursor B-cells or early activated memory 
B-cells (Sanz et al., 2019; Ruschil et al., 2020) .The second is that MIS-C patients lacked the 
expansion of intermediate and non-classical monocytes that is a hallmark of KD (Katayama et 
al., 2000; Hokibara et al., 2016).   The function of these monocyte subsets, normally rare in 
the peripheral blood, is still being defined but they are generally considered to play a role in 
tissue repair (Olingy et al., 2017).  Of particular relevance for KD vasculitis, the expression of 
CX3CR1 on NCM ((Wong et al., 2011) and our scRNAseq data) allows them to closely 
interact with the vasculature (Auffray et al., 2007). Whether the lack of these cells in MIS-C is 
the reason why these patients present with severe shock, which is rare in KD, requires further 
investigation.  
 
A key feature of our study was the analysis of paired samples taken from patients before 
treatment and then shortly afterwards during symptom resolution. This provides a unique 
window into pathogenesis and disease recovery. Shortly after treatment we observed rapid 
changes in both cytokine levels and immune cell phenotype. After only two days, levels of 
proinflammatory chemokines (IP10 and MCP1) and pro-inflammatory cytokines (IL6, IL18) 
had decreased. As noted by others, acute MIS-C patients also had elevated levels of the anti-
inflammatory cytokine IL-10 and we show this also decreases after treatment. However, our 
data shows that the trajectory of recovery is more complex than a simple reversal of the 
hyper-inflammatory state. Thus, we observed substantial increases in plasma arginase levels 
in MIS-C patient 13 and KD patient 2 shortly after treatment.  Although we did not identify the 
cellular source of arginase a prime candidate is neutrophils which were present at particularly 
high frequency in both patients. Arginase-positive immunosuppressive neutrophils have been 
detected in adult COVID-19 patients and other inflammatory conditions(Pillay et al., 2012; Tak 
et al., 2017; Schulte-Schrepping et al., 2020).   
 
Analysis of paired samples also identified complex changes in cellular immunity occurring 
during recovery. Following treatment, classical monocytes expressed more CD163, a marker 
of anti-inflammatory monocytes. This could reflect previously activated monocytes 
transitioning to a less-activated state, no longer shedding CD163 due to downregulation of 
TACE, or the establishment of a new population of activated monocytes with anti-
inflammatory activity(West et al., 2012). Neutrophils also changed during recovery. Thus, 
overall, levels of CD64 decreased but in parallel we also observed the emergence of a new 
population of unusual granulocytes (cluster 3) that expressed CD66b and CD63 but which 
lacked expression of CD35, CD55 and CD11c. Interestingly these three proteins act as 









frequency in healthy donors and acutely ill KD and MIS-C patients but their expression of 
CD64 and their frequency both increased during recovery, in one patient reaching up to 30% 
of total granulocytes. 
 
All of the patients we studied by deep immune profiling received some kind of 
immunomodulatory therapy, either IVIG alone or IVIG in combination with steroids. Without an 
untreated control group for comparison we cannot definitively prove that the immunological 
changes we saw during recovery were treatment induced: they could be a natural process of 
recovery from the acute inflammatory state of MIS-C. However, assuming they were 
iatrogenic in origin then the fact that they occurred in patients that received IVIG alone 
suggests this agent was the cause. Our study therefore reveals potential new modes of action 
for IVIG for validation in larger studies of MIS-C, KD or other inflammatory conditions.   
 
A key aim of our study was to provide a rational basis for MIS-C therapy, which to date has 
empirically followed protocols used to treat KD. These include IVIG, steroids and targeted 
agents that selectively inhibit IL-6 (Tocilizumab), IL-1 (Anakinra) or TNF- (Infliximab) 
(Ahmed et al., 2020; Jiang et al., 2020; Hoste et al., 2021).  The consistent and rapid immune 
changes that occurred in our MIS-C and KD patients shortly after IVIG (including patients who 
received this drug as single agent) are striking, supporting the continued use of IVIG in MIS-C. 
Cases that fail to respond to these agents may need additional therapies. Our results are 
highly relevant for guiding treatment choices in such cases. First, we showed MIS-C patients 
had much higher levels of IL6 relative to IL-1 and TNF- in plasma. Furthermore, MIS-C 
patients also had high levels of IL1-RA (the natural IL1-receptor antagonist protein, present in 
plasma but also produced in recombinant form as the drug Anakinra) and soluble TNF 
receptors (which inhibit TNF-  signalling in vitro (Balcewicz-Sablinska et al., 1998)). This 
combination of low levels of IL-1 and TNF-  but high levels of their natural antagonists 
suggests additional therapeutic inhibition of these pathways may have limited benefit.  Taken 
together, these observations suggest IL-6 inhibition may be the preferred choice for anti-
cytokine therapy.  Second, our data strongly suggest that complement inhibition, with 
appropriate prophylactic antibiotic cover, should be considered as a therapeutic approach. Of 
the 13 MIS-C patients we analysed, 9 (69%) had plasma C5b-9 levels greater than 7.14ug/ml, 
the cut-off value used to stratify adult severe COVID-19 patients for complement inhibitor 
LFG316 therapy in a recent compassionate use study (Zelek et al., 2020b). Our data therefore 
provides a rational basis for testing inhibitors of C5b-9 (such as LFG316 or eculizumab, the 









thrombotic microangiopathy) (Fakhouri et al., 2016) or inhibitors of upstream complement 
activation pathways (Polycarpou et al., 2021) in clinical trials.  
 
Limitations of the study 
This was a non-randomised single centre observational study performed under emergency 
pandemic conditions investigating a rare, newly described disease. Because observational 
studies cannot prove causation we cannot exclude the possibility that the immunological 
changes we observed over time may not be treatment related. Observational studies are 
sensitive to confounders and selection bias but provide a better estimate of clinical practice. 
The potentially confounding effects of patient heterogeneity was reduced in our study by 
ensuring all study patients had serological evidence of prior SARS-CoV-2 infection. 
Experimental variability was controlled as follows. First, our pre- and post-treatment samples 
were obtained from the same individuals, eliminating any inter-individual heterogeneity in the 
longitudinal analysis. Second, all patient and control samples were processed in a single 
laboratory by one of two individuals who followed a standardised protocol. Third, all study 
samples were analysed at the same time in single scRNAseq, mass cytometry, cytokine 
profiling and complement analysis experiments, eliminating inter-assay variance. The number 
of patients and number of cells analysed by scRNAseq was low. Therefore, these data were 
primarily treated as a discovery set, shaping the design of the mass cytometry panel which 
was then applied to a larger number of samples including those analysed by scRNAseq. 
Finally, although the number of patients we recruited is small it is comparable to most other 
MIS-C studies. We highlight that all but one of our acute phase MIS-C samples were collected 
from patients before treatment commenced (the exception being P14, with the first sample 
being collected six hours after IVIG infusion). Our data therefore provide a more accurate 
assessment of acute MIS-C than other studies that have relied entirely upon samples 
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Figure 1. Demographic, clinical and immunological status of 18 paediatric patients with 
Kawasaki disease or MIS-C.  A. Cumulative SARS-CoV-2 positive cases identified by PCR 
testing within the Birmingham area compared to MIS-C cases admitted to Birmingham 
Children’s Hospital PICU.  B. Age of KD and MIS-C patients recruited to this study. C. Clinical 
laboratory results shown for C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), 
ferritin, troponin and vitamin D.  D. Disease severity indicators shown as days hospitalised, 
days in PICU and treatment cycles of IVIG, intravenous steroids and Tocilizumab. E.  Pre-
treatment absolute count of different immune cell subsets expressed as 109 cells/L. F. Left: 
Principal component analysis biplot of clinical laboratory features for patients with MIS-C or 
KD and synthetic healthy controls derived from normal range data. Right: Loading plot 
showing the top 7 features contributing to principal components one and two. G. Correlation 
matrix of clinical features, immune parameters and demographics for the 16 MIS-C patients. 
The strength of each correlation is indicated by colour and statistical significance by asterisks: 
*p<0.05, **P<0.01, ***P<0.001.  Black outline indicates a significant result after 5% false 
discovery rate correction using the Benjamini-Hochberg method. H. Pre-treatment frequency 
of lymphocyte subsets expressed as the absolute number of cells x109/L (left column) or 
percentage of total lymphocytes (right column). I. SARS-CoV-2 ab responses for IgM, IgA and 
IgG.  In panels C, E and H the normal range for each patient, based on their age, is shown by 
the vertical dark grey bar. Data points outside the normal range are drawn with a black 
outline. See also Figure S1.  
 
 Figure 2. Single cell RNA sequence analysis of MIS-C and KD PBMC. A. tSNE 
representation of major cell types and associated FlowSOM clusters in acute stage PBMCs 
from patients KD2, P13, P14 and a convalescent sample from P13 at discharge from PICU. 
All four samples were processed and sequenced in a single experiment. B. tSNE 
representation of PBMCs from each patient sample. C. UMAP representation of monocyte 
cells after re-clustering on monocytes alone in acute stage samples from patients KD2, P13, 
P14 and a convalescent sample from P13 at discharge from PICU. Right hand panel shows 
expression level of selected genes within each cluster. D. UMAP representation of monocyte 
clusters from each patient sample. See also Figures S2, S3, S4, S5, S6, S7, S8.  
 
Figure 3. Mass cytometry analysis of mononuclear cells in whole blood samples from 
healthy children and patients with MIS-C or KD. A. tSNE plots of concatenated flow 
cytometry data from six MIS-C patients or one KD patient at the acute stage of their disease 








and key populations are indicated on the plots. Results from these concatenated datafiles are 
shown throughout this figure.  B. The frequency of each FlowSOM metacluster in the same 
donors expressed as a percentage of total non-granulocyte mononuclear cells are shown as 
box and whisker plots (healthy children and MIS-C) or a blue diamond (KD patient KD2). 
Results of Wilcoxon rank-sum tests comparing the frequency of each cluster in healthy 
children to the frequency in acute MIS-C patients are indicated by: * p<0.05, ** p<0.01, *** 
p<0.001. Non-significant results are not shown and emboldened p value symbols indicate 
significant results after 5% false discovery rate correction using the Benjamini-Hochberg 
method.  C. tSNE plots showing cells within monocyte clusters 17, 20 and 12 for MIS-C 
patients at the acute stage, post IVIG  and at discharge  from PICU alongside plots showing 
cells from a single KD patient or seven healthy children.   D. Trajectory of each of the three 
monocyte clusters over time in seven healthy children or MIS-C patients over time (acute 
stage, post IVIG and PICU discharge). Data from patient P13 is indicated on the plots. E. 
Heatmaps showing the median metal intensity (MMI) of markers expressed on monocyte 
clusters 17, 20 and 12.F. Biaxial plots of CD64 and CD163 expression on cluster 17 
monocytes cells in healthy children or patients with MIS-C or KD at the acute, post-IVIG or 
PICU/hospital discharge stages of disease. Note that all data in the Figure were generated 
from the same seven healthy children, six MIS-C patients (6 acute stage, 4 post IVIG and 2 
discharge samples) or a single KD patient. See also Figures S8, S9, S10.   
 
Figure 4. Mass cytometry of mononuclear cells analysed by manual gating on 
canonical T-cell sub-populations.  A. Percentage of CD8+ and CD4+ T-cells in each of the 
four canonical T-cell sub-populations for seven healthy children, six acute MIS-C patients or a 
single acute KD patient. B. The percentage of each T-cell subpopulation (from the same 
donors shown in panel A) that were positive for HLA-DR are shown as box and whisker plots 
(health donors or MIS-C patients) or a blue diamond (KD patient KD2).   C. Percentage of 
each T-cell sub-population positive for HLA-DR over the course of disease. For all panels the 
data were from seven healthy children, six MIS-C patients (6 acute stage, 4 post IVIG and 2 
discharge (D/C) samples) or a single KD patient.  In panels B and C the results of Wilcoxon 
ranked sum tests comparing the frequency of each cluster in healthy children to MIS-C 
patients (acute stage only in panel B or acute, post-IVIG or discharge stages in panel C) are 
indicated: * p<0.05, ** p<0.01, *** p<0.001. Non-significant results are not shown. 
Emboldened p value symbols indicate significant results after 5% false discovery rate 
correction using the Benjamini-Hochberg method. See also Figure S11.  
 
Figure 5. Mass cytometry analysis of granulocytes in whole blood samples from 








and analyse neutrophil activation in whole blood. B. Heatmaps showing median metal 
intensity (MMI) of markers expressed on manually gated neutrophils. Data are from 
concatenated FCS files from seven healthy children, six MIS-C patients (acute n=6, post-IVIG 
n=4, discharge n=2) and a single KD patient (KD2).  C. tSNE plots of granulocytes from the 
same donors analysed by unsupervised clustering. Top row:  FlowSom metaclusters. Middle 
row: CD64 expression. Bottom row: CD10 expression. D. Upper panels: heatmaps showing 
expression level of different markers in each metacluster for the same donors. Lower panels: 
Trajectory of each metacluster over time, expressed as a percentage of total granulocytes, for 
each of the healthy children and patients. The results of Wilcoxon ranked sum tests 
comparing the frequency of each cluster in healthy children to seven patients (six MIS-C and 
one KD patient) at the acute (n=7), post-IVIG (n=5) and discharge (n=3) timepoints as 
indicated: * p<0.05, ** p<0.01, *** p<0.001. Non-significant results are not shown and 
emboldened p value symbols indicate significant results after 5% false discovery rate 
correction using the Benjamini-Hochberg method. See also Figure S8.  
 
 
Figure 6. Analysis of cytokines in plasma samples from healthy children and patients.  
A. Levels of cytokines in plasma from seven healthy children or six MIS-C patients at the 
acute stage of disease are shown as box and whiskers alongside a blue diamond indicating 
results from a single KD patient (KD2) also at the acute stage. Results of Wilcoxon rank-sum 
tests comparing the concentration of each cytokine in seven healthy children to the 
concentration in eight acute MIS-C patients are indicated by: * p<0.05, ** p<0.01, *** p<0.001. 
Non-significant results are not shown and emboldened p value symbols indicate significant 
results after 5% false discovery rate correction using the Benjamini-Hochberg method.  B. 
Upper panel: principal component analysis biplot of cytokines. Lower panel: loading plot 
showing the top 13 features contributing to principal components one and two. C. Trajectory 
of cytokines over time for the same healthy children and patients shown in panel A at the 
acute, post-IVIG and discharge timepoints. No statistical testing was performed. D. Plots 
showing the concentration (upper panel) and enzyme activity (lower panel) of arginase over 
time in plasma samples from seven healthy children, MIS-C patient P13 and KD patient KD2. 
E. Results of linear regression analysis of the acute disease stage absolute counts of 
lymphocytes, monocytes or neutrophils against the plasma arginase concentration after IVIG 
treatment. The R2 and statistical significance of each regression model is shown on the plot 
with the shaded area indicating the 95% confidence interval. See also Figure S8. 
 
Figure 7. Analysis of complement in plasma samples from healthy children and 








(factor H, factor I) and activation products (iC3b, C5b-9/TCC) in plasma samples from seven 
healthy children (HC), thirteen MIS-C patients at the acute stage of disease and nine of these 
patients shortly after IVIG treatment. The horizontal line indicates the median value for 
patients and controls. Results of Wilcoxon rank-sum tests comparing the frequency of each 
cluster in healthy children to that in MIS-C patients at the acute or the post IVIG timepoints are 
indicated by: * p<0.05, ** p<0.01, *** p<0.001. Non-significant results are not shown and 
emboldened p value symbols indicate significant results after 5% false discovery rate 
correction using the Benjamini-Hochberg method. Also shown on the plot, but not included in 
the statistical analysis, are the results from a single acute stage KD patient (blue diamond 
symbol, patient KD2). The level of C5b-9 for patient P13, who had severe disease, is 















Further information and any requests should be directed to and will be fulfilled by the lead 
contact, Graham Taylor (g.s.taylor@bham.ac.uk). 
 
Materials availability 
This study did not generate new unique reagents.  
 
Data and code availability 
Raw and processed single cell RNA-seq data have been deposited online in GEO and are 
publicly available (www.ncbi.nlm.nih.gov/geo/ accession number GSE183716).    
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Ethical approvals and patient demographic information   
All patient samples were obtained Birmingham Children’s Hospital as part of a Health 
Research Authority approved study (TrICICL) reviewed and approved by South of 
Birmingham Research Ethics Committee (REC: 17/WM/0453, IRAS: 233593). Demographic 
and clinical information for each patient is provided in Table S1. Samples from seven healthy 
children (aged 12 years) were obtained via the Coronavirus Immunological Analysis study 
approved by North West - Preston Research Ethics Committee (REC: 20/NW/0240, IRAS: 
282164). This study was performed in accordance with the declaration of Helsinki and written 
informed consent was obtained from all participants or their legal guardians.  
 
METHOD DETAILS 
Sample processing and storage 
Peripheral blood samples from healthy donors or paediatric patients presenting with 
suspected MIS-C or KD were collected in EDTA and serum vacutainer tubes and stored at 
room temperature before processing. Whole blood was preserved using Cytodelics stabiliser 
and peripheral blood mononuclear cells (PBMCs) isolated using SepMate tubes as per the 
manufacturer’s protocol and cryopreserved in a solution of 70% fetal calf serum and 10% 
dimethyl sulfoxide using an optimised protocol (Kreher et al., 2003). Plasma collected during 
PBMC isolation and serum separated by centrifugation were stored as frozen aliquots at -
80°C.   
 









Antibodies specific for the SARS-CoV-2 spike protein were detected by ELISA (Perez‐ Toledo 
et al., 2020).  ELISA plates coated with stabilized, trimeric spike glycoprotein truncated at the 
transmembrane region (The Binding Site, UK) were blocked with Stabilcoat solution and 
serum samples pre-diluted at a 1:40 dilution using a Dynex Revelation automated liquid 
handler (Dynex, USA) were added. Bound antibodies were detected using sheep-anti-human 
horseradish peroxidase (HRP)-conjugated polyclonal antibodies against IgG (1:16,000), IgA 
(1:2000), and IgM (1:8000), TMB core and orthophosphoric acid as a stop solution (all from 
The Binding Site, UK). Optical densities at 450nm were measured using the Dynex Revelation 
automated liquid handler. IgG, IgA, and IgM ratio-cutoffs were determined based on running 
90 pre-2019 negative serum samples. Ratio values > 1, are classed as positive and ratio 
values < 1 are classed as negative for anti-SARS-CoV-2 spike IgG, IgA or IgM antibodies. 
Clinical laboratory tests were performed at the Birmingham Children’s Hospital’s clinical 
laboratory. Lymphocyte subset enumeration was performed by the University of Birmingham 
Clinical Immunology Service using Trucount tubes and a FACSCanto-II cytometer (Key 
Resources Table). Paediatric reference values were obtained from previously published data 
(Comans-Bitter et al., 1997).  
 
scRNA sequencing 
All blood samples used for single cell RNA-seq were cryopreserved within four hours of 
phlebotomy.  Cryopreserved PBMCs were recovered, feature barcoded using DNA-
conjugated antibodies and libraries constructed using 10X Genomics reagents (Key 
Resources Table) according to manufacturer’s instructions. Sequencing was performed on an 
Illumina NextSeq 500 platform, sequencing 419 million reads of 150 bases. All samples were 
recovered, processed and sequenced at the same time.  
 
Mass Cytometry  
Antibodies were purchased pre-conjugated from Fluidigm or unconjugated from other 
suppliers and conjugated in house using Fluidigm Maxpar reagents (Key Resources Table 
and Table S2).  Whole blood samples stored in Cytodelics stabiliser media were thawed and 
processed as per manufacturer's protocol. For staining, a master-mix of all 38 phenotyping 
antibodies was prepared by adding the appropriate pre-tested dilutions into filtered cell stain 
media (CSM – Key Resources Table). The antibody cocktail was then filtered through a 
100um spin column before use.  Cells were incubated with Fc block for 10 minutes, antibodies 
were added and incubated for further 30 minutes. The samples were washed twice with CSM 
then fixed overnight with freshly prepared 1.6% formaldehyde. The following day, cells were 
incubated with iridium intercalator solution for one hour then analysed on a Helios mass 









acquisition cells were washed once in CSM buffer and twice in deionised water. Prior to 
acquisition, each sample was reconstituted in deionised water spiked with EQ calibration 
beads and filtered through a 70μm cell strainer.  
 
Cytokine and complement quantification  
Cytokines were quantified in plasma samples using three BioLegend LEGENDplex cytokine 
detection assays performed in parallel Assay beads were measured using an LSRFortessa X-
20 cytometer.  Myeloperoxidase was measured in plasma samples by ELISA.  Complement 
proteins, regulators and activation markers were measured using established in-house 
ELISAs (Kopczynska et al., 2018; Zelek et al., 2020a). Nunc MaxiSorp plates were coated 
with capture antibody at 4⁰C overnight, then blocked (1h 37⁰C) with 2% bovine serum albumin 
(BSA) in phosphate buffered saline + 0.05% Tween-20 (PBS-T). After washing with PBS-T, 
protein standards or serum samples diluted in 0.2% BSA in PBS-T were added to plates in 
duplicate for 90 minutes at 37⁰C. Plates were washed 3x with PBS-T, then incubated with 
detection antibody for 1h (depending on the assay, some detection antibodies were labelled 
with HRP). For assays using unlabelled detection reagents plates were washed 3x with PBS-
T then incubated with HRP-conjugated secondary antibody as above. After washing 3x with 
PBS-T assays were developed using either o-phenylenediamine dihydrochloride or 3,3',5,5'-
tetramethylbenzidine and stopped with 5% sulphuric acid (see Key Resources Table for full 
details) 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
ScRNAseq Data Pre-processing and Quality Control 
Processing of raw reads including 10X barcode-aware demultiplexing from BCL to FASTQ 
files, transcriptome alignment to human genome assembly GRCh38 and unique molecular 
identifier (UMI) counting were performed using the 10X Cell Ranger pipeline version 3.1.0 with 
GRCh38-version 3.0.0 as the reference. Seurat v3.1.5 (Butler et al., 2018) was used for 
sample merging, quality control (QC), clustering and reporting. Both gene expression (RNA) 
and antibody- derived tag (ADT) assays were loaded from the CellRanger count platform into 
a Seurat object for each sample excluding cells with less than 200 genes and features 
detected in less than 3 cells. The four samples were then merged to create a single 
aggregated object. As application of batch effect correction (data integration) did not affect our 
conclusions we decided that batch effects were not a concern and chose to present the 
unaltered data. QC was conducted on both assays separately. For the RNA assay, to mitigate 
the influence of sex on clustering and differential expression, the XIST and RSP4Y1 genes 









1000 and mitochondrial percentage less than 15% were kept for further processing. The gene 
expression data was normalised using the ‘LogNormalize’ method with the scale.factor set to 
the default 10000. 1500 variable features were identified using the ‘vst’ method of the 
‘FindVariableFeatures’ function. The assay was finally scaled with the number of counts and 
mitochondrial percentage variables regressed. The ADT assay was first used to identify dead 
cells or cell doublets by removing double positive instances of lineage markers according to 
the following criteria: CD14 > 60 & CD19 > 50, CD19 > 40 & CD3 > 40, CD14 > 80 & CD3 > 
50 and CD3 < 50 & gamma-delta > 400. The assay was then centred log-ratio (CLR) 
normalised and scaled with default parameters. The remaining object comprised 10,031 cells 
with 17,583 features. 
 
PBMC Clustering of scRNAseq data 
Both the RNA and ADT assays were used to compute 50 principal components. These 
principal components were then used as input into the ‘FindNeighbours’ function and 
subsequently the ‘FindClusters’ function with resolution set to the default value of 1, resulting 
in 19 clusters which were visualised using tSNE. The clusters were manually annotated from 
expression of lineage markers both at the transcript (RNA) and protein (ADT) levels. To check 
our samples for potential T-cell activation we evaluated our data for expression of genes 
previously identified by scRNAseq analysis as being upregulated upon T-cell stimulation 
(Szabo et al., 2019). 
 
Monocyte Clustering of scRNAseq data 
To examine the monocyte populations in finer detail, we extracted clusters 4, 6, 9, 10 and 13 
from Figure 1E using the ‘Subset’ function. As monocytes were abundant within each sample, 
all monocyte clusters were included (2248 monocytes extracted). Both assays were 
normalized separately (RNA: ‘LogNormalize’ & ADT: ‘CLR’). The ‘vst’ method was used to find 
the 2000 most variable features within the RNA assay and the data was scaled with the 
variables ‘number of counts’ and ‘percent mitochondria’ regressed. The ADT assay was 
scaled with default parameters. In this instance, 100 principal components were used in the 
‘RunPCA’ function with the top 50 of those components used to find cell neighbours and 
clusters. The UMAP reduction was selected here as the clusters visually displayed a better 
path from classical to intermediate to non-classical monocytes over the tSNE reduction. Nine 
clusters were originally generated with further assessment resulting in the identification of 
seven monocyte clusters. CD14 and CD16 markers from the ADT assay were used to classify 
classical (CD14+), non-classical (CD16+) and intermediate (CD14+CD16+) monocyte 
populations. Further differential expression analysis of the RNA assay was used to define 










Differential gene expression was conducted between the acute samples and the convalescent 
sample for CD14+ monocytes, NK, CD8+ T cells, CD4+ T cells and B cells with the 
‘FindMarkers’ function in Seurat using MAST (Finak et al., 2015). Both up and down regulated 
genes were identified. Gene ontology was conducted with the resulting gene lists using 
EnrichR (Chen et al., 2013), focusing on the biological processes subset 
(‘GO_Biological_Processes’). Go terms were simplified using Revigo software (Supek et al., 
2011).  
 
Mass Cytometry  
Mass cytometry data was normalised using the CyTOF data acquisition software (Fluidigm). 
Normalised data were exported as FCS (Flow Cytometry Standard) files and uploaded to 
Cytobank for doublet discrimination and analysis by manual gating and unsupervised 
methods. Singlet cells from healthy children or MIS-C patients at different clinical stages were 
examined individually or as concatenated FCS files comprising an equal number of cells from 
each individual. Each FCS file was then downsampled to 16,000 cells (mononuclear cells) or 
22,000 cells (granulocytes) for analysis.  Gating strategies are provided in supplementary 
Figure S11.  Dimensionality reduction and clustering were performed in Cytobank using the 
ViSNE implementation of tSNE and FlowSOM respectively.   
 
Legendplex Cytokine Measurement 
Data were analysed using the LEGENDplex data analysis software provided by the 
manufacturer, following their recommendations.   
 
Data analysis and statistical testing 
Time series of positive cases by testing date for England was downloaded from the UK 
Government Department of Social Care and Public Health England website: 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public#time-series- 
documents. Data shown are results for area ‘Birmingham’.  Data analysis was performed in R 
version 4.0.3 using the lm, marixStats and matrixTests packages and figures prepared using 
ggplot2. Box and whisker plots show the standard Tukey representation (median, interquartile 
range and whiskers extending to the largest and smallest values within 1.5 times the 
interquartile range with outliers plotted as points). We report the significance of each test and, 
where necessary, correct for multiple comparisons by controlling the false discovery rate 









each test are provided in figure legends. When analysing patients samples collected at 
different timepoints (acute, post IVIG and discharge) we compared values from each timepoint 
to the healthy donor values. Principal component analysis was performed using the PCAtools 
package in R. For the PCA analysis of clinical laboratory data we did not have access to data 
from healthy individuals but normal reference values were available. Therefore, to allow 
patients to be compared to the reference values (some of which vary by age or gender, Figure 
1) we generated synthetic healthy controls. For each patient we generated 10 synthetic 
controls by randomly selecting values for each feature within the normal range that would be 
expected for that patient based on their age and gender. Following PCA the synthetic healthy 
donors therefore indicate where healthy donors would localise in the lower dimensionality 
projection.   For cytokines (Figure 7) the PCA plot was prepared using the 24 features with 
highest variance (variance > 300).  PCA analyses were performed using scaled and centred 
values. Graphs were prepared using ggplot2 or Prism software version 8.  The correlation 
matrix (Figure 1) was produced in using publicly available code downloaded from GitHub on 
the 3rd November 2020 (Wherry research group, University of Pennsylvania). Any additional 
information required to reanalyse the data reported in this paper is available from the lead 
contact upon request. 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Totalseq-B Human TBNK panel Biolegend Cat#399902 
Totalseq-B anti-human TCR g/d Biolegend Cat#331233 
Totalseq-B anti-human CD45RO Biolegend Cat#304257 
Anti-CD41 / CD61  (clone A2A9/6,purified)  Biolegend Cat#359802 
Anti-CD42a (clone REA209, purified)  Miltenyi Cat#130-122-338 
Anti-CD16 (clone 3G8, purified) Biolegend Cat#302002 
Anti-CD14 (clone RMO52, purified) Beckman Coulter Cat#IM0643 
Anti-CD2 (clone TS1/8, purified) Biolegend Cat#309219 
Anti-CD8 (clone SK1, purified) Biolegend Cat#344727 
Anti-CD57 (clone HCD57, purified) Biolegend Cat#359602 
Anti-CD36 (clone 5-271, purified) Biolegend Cat#336202 
Anti-FceR1 (clone AER-37, purified) Biolegend Cat#334602 
Anti-CD45 (clone HI30, purified) Biolegend Cat#304002 
Anti-CD19 (clone HIB19, purified) Biolegend Cat#302247 
Anti-CD32 (clone FUN-2, purified) Biolegend Cat#303202 
Anti-CD4 (clone RPA-T4, conjugated to 145Nd) Fluidigm Cat#3145001B 
Anti-IgD (clone IA6-2, conjugated to 146Nd) Fluidigm Cat#3146005B 
Anti-CD11c (clone S-HCL-3, purified) Biolegend Cat#371502 
Anti-CD69 (clone REA824, purified) Miltenyi Cat#130-124-326 
Anti-CD64 (clone 10.1, purified) Biolegend Cat#305029 
Anti-CD62L (clone DREG56, purified) Biolegend Cat#304802 
Anti-CD123 (clone 6H6, purified) Biolegend Cat#306002 









Anti-CD177 (clone MEM-166, purified) Biolegend Cat#315802 
Anti-CD86 (clone IT2.2, purified) Biolegend Cat#305402 
Anti-CD39 (clone A1, purified) Biolegend Cat#328202 
Anti-CD163 (clone GHI/61, purified) Biolegend Cat#333602 
Anti-CD55 (clone JS11, purified) Biolegend Cat#311302 
Anti-CD56 (clone NCAM16.2, conjugated to 163Dy) Fluidigm Cat#3163007B 
Anti-CD95 (clone DX2, purified) Biolegend Cat#305602 
Anti-CD35 ((clone E11, purified) Biolegend Cat#333402 
Anti-CD27 (clone L128 conjugated to 167Er) Fluidigm Cat#3167006B 
Anti-CD10 (clone HI10a, purified) Biolegend Cat#312202 
Anti-CD25 (clone 2A3 conjugated to 169Tm) Fluidigm Cat#3169003B 
Anti-CD3 ((clone UCHT1, purified) Biolegend Cat#300402 
Anti-CD40 (clone HB14, purified) Biolegend Cat#313002 
Anti-CXCR4 (clone 12G5 conjugated to 175Lu) Fluidigm Cat#3175001B 
Anti-CD63 (clone H5C6, purified) Biolegend Cat#353039 
Anti-CD235 (clone HI264, purified) Biolegend Cat#349102 
Anti-CD38 (clone HIT2, purified) Biolegend Cat#303502 
Anti-HLA-DR (clone L243, purified) Biolegend Cat#307602 
Biological samples   
Whole Blood, PBMC, serum and plasma from MIS-C 
patients, KD patients and healthy children.  
N/A N/A 
Chemicals, peptides, and recombinant proteins 
Stabilised trimeric SARS-CoV2 Spike protein The Binding Site Cat#MK654 
Stabilcoat Sigma Aldrich Cat#S0950 
Sheep anti-human IgG HRP The Binding Site Cat#MK654 
Sheep anti-human IgM HRP The Binding Site Cat#MK654 
Sheep anti-human IgA HRP The Binding Site Cat#MK654 
TMB The Binding Site Cat#MK654 
Orthophosphoric acid The Binding Site Cat#MK654 
Cytodelics whole blood processing kit Cytodelics ab Cat#hC002-1000 
Maxpar X8 Antibody Labelling kits (various isotopes) Fluidigm various 
Maxpar MCP9 Antibody Labelling kits (various isotopes) Fluidigm various 
EQ four element calibration beads Fluidigm Cat#201078 
Trustain Fc receptor blocking solution Biolegend Cat#422302 
Cell-ID iridium intercalator  Fluidigm Cat#201192B 
Cell Staining Media (CSM, phosphate buffered saline + 
0.5% foetal bovine serum + 0.02% sodium azide) 
Prepared in house N/A 
Nunc MaxiSorp Plates Thermo Fisher Cat#44-2404-21 
Tween 20 VWR  Cat#663684B 
Bovine Serum Albumin Thermo Fisher  Cat#10257123 
Sigmafast OPD Sigma Aldrich Cat#P9187 
TMB Thermo Fisher Cat#555214 
Mouse anti-TCC (aE11)  Hycult Cat#HM2167-1MG 
Mouse anti-TCC (E2 conjugated to biotin) E2: in-house 
Biotin: Thermo Fisher 
 
Cat#21327 
Mouse anti-C9 (B7) In house  
Polyclonal rabbit anti-C9 (conjugated to HRP) In house  
Mouse anti-factor I (7B5) In house  
Polyclonal rabbit anti-factor I In house  
Mouse anti-C1q (9H10) In house  
Polyclonal rabbit anti-C1q In house  









Mouse anti-factor H (35H9) In house  
Mouse anti-iC3b (clone 9) In house  
Mouse anti-iC3b (bH6, conjugated to HRP in house) Hycult Cat#HM2168 
Mouse anti-C1 inhibitor In house  
Polyclonal rabbit anti-C1 inhibitor In house  
Polyclonal rabbit anti-C4 In house  
Polyclonal rabbit anti-C4 (conjugated to HRP) In house  
Polyclonal rabbit anti-C3  In house  
Polyclonal rabbit anti-C3 (conjugated to HRP) In house  
EZlink HRP labelling kit Thermo Fisher Cat#31489 
Donkey anti-rabbit IgG HRP Jackson 
ImmunoResearch 
Cat#711-035-152 
Goat anti-human IgM HRP Thermo Fisher Cat#A18841 
Streptavidin HRP Thermo Fisher Cat#21130 
TCC protein Purified in house  
C9 protein Purified in house  
Factor I protein Purified in house  
C1q protein Purified in house  
C3 protein CompTech Cat#A113 
C4 protein Purified in house  
Factor H protein Purified in house  
iC3b protein CompTech Cat#A115 
C1 inhibitor protein Purified in house  
Critical commercial assays 
BD Multitest trucount tubes (6 colour) Beckton Dickinson Cat#337166 
Legendplex macrophage.microglia 13-plex panel  Biolegend Cat#740502 
Legendplex Human Inflammation panel 1 Biolegend Cat#740808 
Legendplex Inflammation panel 2 Biolegend Cat#740775 
Myeloperoxidase ELISA Thermo Fisher Cat#BMS2038INST 
Chromium Next GEM Single cell 3’ GEM, Library and 
Gel Bead kit v3.1 
10x Genomics Cat#1000128 
Chromium Next GEM Chip G Single Cell Kit 10x Genomics Cat#1000127 
Chromium i7 Multiplex Kit 10x Genomics Cat#220103 
Chromium Single Cell 3' Feature Barcode Library Kit 10x Genomics Cat#1000079 
Illumina NextSeq High 150 v2.5 Illumina Cat#20024907 
Illumina NextSeq Mid 150 v2.5 Illumina Cat#20024904 
Deposited data 
Single cell RNA-seq data (deposited to GEO) www.ncbi.nlm.nih.gov/
geo/ 
GSE183716 
Software and algorithms 
R (version 4.0.3) https://cran.r-
project.org 
N/A 





Revigo http://revigo.irb.hr N/A 
Prism GraphPad N/A 
Legendplex Cytokine Analysis Software  Biolegend N/A 
Cytobank Cytometry Analysis Software Cytobank N/A 
Other 









LSRFortessa X-20 Cytometer Beckton Dickinson N/A 
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The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in 
Children (MIS-C) from acute disease to recovery.     
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 Granulocyte frequency correlates with MIS-C disease severity at presentation.  
 
 Recovering patients have increased CD163 on monocytes and new atypical neutrophils. 
 
 Cytokine profile of acute MIS-C suggests inhibiting IL6 rather than IL1 or TNF. 
 
 Raised plasma C5b-9 identifies complement inhibitors as potential MIS-C therapy. 
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